Form 4: Recursion Pharmaceuticals Director Executes Stock Sale

Director Christopher Gibson sold 40,000 shares of Recursion Pharmaceuticals Class A Common Stock via a pre-arranged 10b5-1 plan.

Summary

• Director Christopher Gibson converted 40,000 shares of Class B Common Stock into Class A Common Stock.
• The converted shares were subsequently sold at a price of $3.62 per share.
• The transaction was executed on June 5, 2026, pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2025.
• Following the transaction, the director retains direct ownership of 883,735 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed through a pre-planned 10b5-1 arrangement, which is standard practice for corporate insiders.

Positives

• The sale was conducted under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell stock without triggering concerns regarding non-public information.

Negatives

• The transaction represents a divestment of equity by a key insider, which may be perceived as a lack of confidence in short-term price appreciation.

Risks

• Continued reliance on Rule 10b5-1 plans for liquidity by company insiders.
• Market sensitivity to insider selling activity in the biotechnology sector.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a common practice in the biotech industry, often used by executives to diversify personal holdings while maintaining compliance with SEC regulations.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for corporate insiders to manage equity compensation and liquidity.
• The volume of shares sold is relatively small compared to the director's total beneficial ownership.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and represents a small portion of the director's total holdings.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Recursion Pharmaceuticals, RXRX, Insider Trading, Form 4, Biotech, Equity Sale